[Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4]. / Minimalinvasive Therapien des benignen Prostatasyndroms : Die deutsche S2e-Leitlinie 2023 Teil 4/4.
Urologie
; 63(1): 58-66, 2024 Jan.
Article
em De
| MEDLINE
| ID: mdl-38193989
ABSTRACT
BACKGROUND:
Lower urinary tract symptoms suggestive for benign prostatic obstruction (LUTS/BPO) are one of the most frequent diseases in men and can have a significant impact on quality of life. Instrumental therapies are common, and many patients seek minimally invasive treatment options.OBJECTIVE:
Presentation and evidence-based evaluation of the minimally invasive therapy for benign prostatic syndrome. MATERIALS ANDMETHODS:
Summary and overview of chapters 11-13 on minimally invasive therapies for LUTS/BPO of the current long version of the German S2e guideline.RESULTS:
In case of absolute indication for surgery or after unsatisfactory or undesired medical therapy, minimally invasive treatments such as UroLift® (Neotract Inc., Pleasanton, CA, USA), Rezá¿¡m™ (Boston Scientific, Malborough, MA, USA), iTIND™ (Olympus America Inc., Westborough, MA, USA), and prostatic artery embolization (PAE) can be considered. These indirect/delayed ablative therapies offer lower morbidity and the possibility of performing them under local anesthesia, but they are inferior to direct ablative/resective techniques in terms of effectiveness and sustainability.CONCLUSIONS:
The updated German S2e guideline summarizes evidence-based recommendations for new minimally invasive therapies for LUTS/BPO, which present alternative treatment options for selected patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hiperplasia Prostática
/
Obstrução Uretral
/
Embolização Terapêutica
/
Sintomas do Trato Urinário Inferior
Tipo de estudo:
Etiology_studies
/
Guideline
Idioma:
De
Revista:
Urologie
Ano de publicação:
2024
Tipo de documento:
Article